Estimated benefits of glycemic control in microvascular complications in type 2 diabetes

Annals of Internal Medicine

Volumn 127, Issue 9, 1997, Pages 788-795

  Vijan, Sandeep ^a,b   Hofer, Timothy P ^a   Hayward, Rodney A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLINDNESS; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PRIORITY JOURNAL; PROBABILITY;

EID: 0030662005     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-9-199711010-00003     Document Type: Article

References (68)

1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-88, 252-61.
2. Engerman R, Bloodworth JM Jr, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes. 1977;26:760-9.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864-71.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86.
5. Peters AL, McCulloch DK, Hayward RA, Deraco MR, Morrison AD. Case one: Too little too late - delayed diagnosis of NIDDM. Journal of Clinical Outcomes Management. 1994;1:9-26.
6. Teuscher A, Reinli K. Severe hypoglycaemia in Diabetes Control and Complications Trial [Letter]. Lancet. 1994;343:1097-8.
7. Colwell JA, Clark CM Jr. Forum Two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):178-9.
8. Colwell JA. Should we use intensive insulin therapy after oral agent failure in type II diabetes? Diabetes Care. 1996;19:896-8.
9. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):90-6.
10. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med. 1989;111:788-96.
11. Dwyer MS, Melton LJ 3d, Ballard DJ, Palumbo PJ, Trautmann JC, Chu CP. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care. 1985;8:316-22.
12. Hayward RA, Manning WG, Kaplan SH, Wagner E, Greenfield S. Starting insulin therapy in type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997; [In press].
13. Clark CM Jr. Where do we go from here? Ann Intern Med. 1996;124(1 Pt 2):184-6.
14. The relationship of glycemic exposure (HBA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1995;44:968-83.
15. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology. 1988;95:1340-8.
16. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071-8.
17. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. EDTRS Rrport number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786-806.
18. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med. 1992;152:610-6.
19. Harris MI. Medical care for patients with diabetes. Epidemiologic aspects. Ann Intern Med. 1996;124(1 Pt 2):117-22.
20. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ. 1995;311:973-7.
21. Cooper ME, Frauman A, O'Brien RC, Seeman E, Murray RM, Jerums G. Progression of proteinuria in type 1 and type 2 diabetes. Diabet Med. 1988; 5:361-8.
22. Baba T, Tomiyama T, Kodama T, Murabayashi S. Glycaemic control and progression of nephropathy in proteinuric NIDDM patients [Letter]. Diabetes Res Clin Pract. 1992;16:157-9.
23. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br Med J (Clin Res Ed). 1983;286:598-602.
24. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med. 1996;124(1 Pt 2):86-9.
25. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7.
26. Liu QZ, Pettitt DJ, Hanson RL, Charles MA, Klein R, Bennett PH, et al. Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses. Diabetologia 1993;36:428-32.
27. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323-8.
28. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
29. Morisaki N, Watanabe S, Kobayashi J, Kanzaki T, Takahashi K, Yokote K, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994;42:142-5.
30. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;100:1061-70.
31. Powrie JK, Watts GF, Ingham JN, Taub NA, Talmud PJ, Shaw KM. Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes. BMJ. 1994;309:1608-12.
32. Rudberg S, Ullman E, Dahlquist G. Relationship between early metabolic control and the development of microalbuminuria - a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:1309-14.
33. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet, 1986;2:1300-4.
34. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A, Mathiesen ER. Natural history of diabetic complications: early detection and progression. Diabet Med. 1991;8:S33-7.
35. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-5.
36. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275-9.
37. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-60.
38. John L, Rao PS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care. 1994;17:888-90.
39. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985; 78:785-94.
40. National Center for Health Statistics. Vital statistics of the United States, 1991. v II. Mortality, part B. Washington, DC: U.S. Public Health Service; 1995.
41. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-31.
42. Muggeo M, Verlato G, Bonora E, Bressan F, Girotto S, Corbellini M, et al. The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia. 1995;38: 318-25.
43. Panzram G, Zabel-Langhennig R. Prognosis of diabetes mellitus in a geographically defined population. Diabetologia. 1981;20:587-91.
44. Krolewski AS, Czyczyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics Diabetologia. 1977;13:345-50.
45. Vander Zwaag R, Runyan JW Jr, Davidson JK, Delcher HK, Mainzer I, Bagget HW. A cohort study of mortality in two clinic populations of patients with diabetes mellitus. Diabetes Care. 1983;6:341-6.
46. Shenfield GM, Elton RA, Bhalla IP, Duncan LJ. Diabetic mortality in Edinburgh. Diabetes Metab. 1979;5:149-58
47. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates Diabetologia. 1990;33:538-41.
48. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154: 2473-9.
49. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia. 1990;33:542-8.
50. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med. 1995;12:149-55.
51. Jarrett RJ, Viberti GC, Argyropoulus A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabet Med. 1984;1:17-9.
52. Matlock MB, Keen H, Viberti GC, el-Gohari MR, Murrells TJ, Scott GS, et al. Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1988;31:82-7.
53. Medhi J. Stochastic Processes. 2d ed. New Delhi: J Wiley; 1994.
54. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
55. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249-58.
56. Klein R, Klein BE, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care. 1993;16:1325-30.
57. End-stage renal disease associated with diabetes - United States, 1988. MMWR Morb Mortal Wkly Rep. 1989;38:546-8.
58. Klein R, Klein B. Vision disorders in diabetes. In: Diabetes in America: Diabetes Data Compiled 1984. Bethesda, MD: U.S. Department of Health and Human Services; 1985:1-2.
59. Standards of medical care for patients with diabetes mellitus. American Diabetes Association. Diabetes Care. 1994;17:616-23.
60. Henry RR, Genuth S. Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):175-7.
61. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ. 1993;306:1235-9.
62. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-23.
63. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interaction with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361-9.
64. Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984;27:568-73.
65. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-84.
66. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43: 960-7.
67. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.
68. Avorn J. Benefit and cost analysis in geriatric care: turning age discrimination into health policy. N Engl J Med. 1984;310:1294-301.